Flash Finance

Marksans Pharma LimitedMARKSANSCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹311.00
MCap ₹14,093 Cr · P/E 27.0
Marksans Pharma Limited — Stock analysis & AI research Marksans Pharma Limited — Multibagger AI analysis Marksans Pharma Limited — Seasonality — best & worst months Marksans Pharma Limited — Technical indicators & charts Marksans Pharma Limited — Technical setup — score, trend, support & resistance Marksans Pharma Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Low Debt Stocks📋 Small Cap Stocks List📋 Quality Stocks📋 Quality + Momentum Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹841 Cr
Sales · Jun 2026
+35.6% YoY
₹213 Cr
Operating Profit · Jun 2026
+113.0% YoY
25.3%
OPM % · Jun 2026
+57.1% YoY
₹159 Cr
Net Profit · Jun 2026
+174.8% YoY
₹3.47
EPS · Jun 2026
+169.0% YoY

📝 Marksans Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Marksans Pharma Limited reported revenue of ₹841 crore for the quarter ended June 2026 (Q1 FY27), up 35.6% from ₹620 crore in the same quarter last year, and down 1.8% sequentially over the March 2026 quarter.

Net profit rose 174.8% year-on-year to ₹159 crore, from ₹58 crore. Earnings per share (EPS) came in at ₹3.47.

Operating profit stood at ₹213 crore — an operating margin (OPM) of 25.3%, compared with 16.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Marksans Pharma Limited posted revenue of ₹2,950 crore, a growth of 12.5% over FY25, with a net profit of ₹420 crore (up 9.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,171 crore with a net profit of ₹521 crore.

Valuation snapshot

At the current price of ₹311.00, MARKSANS has a market capitalisation of ₹14,093 crore and a trailing P/E of about 27.0.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 2nd-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 43.87%, foreign institutional investors (FIIs) 19.06%, domestic institutional investors (DIIs) 5.54%, public shareholders 31.53% of Marksans Pharma Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹14,093 Cr
Current Price ?
₹311.0
P/E ?
27.03above ind
Industry P/E ?
21.30
P/B ?
4.66
P/S ?
4.44
P/FCF ?
42.84
Enterprise Value ?
₹14,436 Cr
EV/EBITDA ?
20.25
PEG ?
1.69
Earnings Yield ?
4.2%
Dividend Yield ?
0.25%
Profitability & Returns
Sales (TTM) ?
₹3,171 Cr
OPM ?
22.5%
Profit after tax (TTM) ?
₹521 Cr
EPS (TTM) ?
₹11.51
ROCE ?
19.0%
ROE ?
17.2%
ROA ?
13.5%
Growth
Sales — latest qtr ?
₹841 Cr
PAT — latest qtr ?
₹159 Cr
YoY qtr sales growth ?
35.6%
YoY qtr profit growth ?
174.8%
Sales growth (3y) ?
17%
Sales growth (5y) ?
16%
Profit growth (3y) ?
16%
Profit growth (5y) ?
12%
Financial Health
Debt ?
₹343 Cr
Debt to Equity ?
0.11
Interest Coverage ?
20.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
43.87%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
16.4%
Return 6 months ?
73.5%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 480486500531586560591642682708620720754856841 +35.6% -1.8%
Operating Profit 77110102114133110128136139127100144161195213 +113.0% +9.2%
Other Income 1811101951715112815622203525 +323.4% -27.4%
Interest 222235333366667 +16.7% +16.7%
Depreciation 131414182221202021232327242425 +8.1% +3.6%
Profit Before Tax 791049711411310012012514311677133151200207 +168.3% +3.3%
Net Profit 6283708483788998105915899114149159 +174.8% +7.0%
EPS 1.561.971.521.841.841.731.962.132.312.001.292.172.503.273.47 +169.0% +6.1%
OPM % 16.0% 22.5% 20.4% 21.4% 22.7% 19.6% 21.7% 21.1% 20.4% 17.9% 16.1% 20.0% 21.4% 22.8% 25.3% +57.1% +11.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,622 Cr ₹2,950 Cr ₹3,171 Cr +12.5%
Operating Profit ₹530 Cr ₹600 Cr ₹713 Cr +13.2%
OPM % 20.21% 20.34% 22.49% +0.6%
NPM % 14.60% 14.24% 16.44% -2.5%
Other Income ₹69 Cr ₹83 Cr ₹102 Cr +20.5%
Depreciation ₹84 Cr ₹98 Cr ₹100 Cr +17.2%
Interest ₹11 Cr ₹24 Cr ₹25 Cr +113.8%
EBIT ₹446 Cr ₹502 Cr ₹613 Cr +12.5%
PBT ₹504 Cr ₹561 Cr ₹691 Cr +11.3%
Tax ₹96 Cr — ₹47 Cr —
Net Profit ₹383 Cr ₹420 Cr ₹521 Cr +9.7%
EPS ₹8.40 ₹9.23 ₹11.41 +9.9%
Material Cost ₹888 Cr — ₹359 Cr —
Employee Cost ₹253 Cr — ₹114 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CWIP 1092715 -44.4%
Equity Capital 45454545 +0.0%
Reserves 1,7002,0202,4222,978 +23.0%
Borrowings 123244322343 +6.5%
Other Liabilities 322372451494 +9.5%
Total Liabilities 2,1902,6813,2403,861 +19.2%
Fixed Assets 4867769821,088 +10.8%
Investments 12710 -100.0%
Other Assets 1,6941,8692,2302,758 +23.7%
Total Assets 2,1902,6813,2403,861 +19.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 237230207458 +121.3%
Cash from Investing Activity -259-141-49-248 -406.1%
Cash from Financing Activity 198-69-65-71 -9.2%
Net Cash Flow 1762193139 +49.5%
Free Cash Flow 1842235329 +840.0%
CFO/OP 88%77%63%100% +58.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 82767580 +6.7%
Inventory Days 192217270278 +3.0%
Days Payable 91949896 -2.0%
Cash Conversion Cycle 183199247261 +5.7%
Working Capital Days 122129142149 +4.9%
ROCE % 22%21%20%19% -5.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 43.87%43.87%43.87%43.87%43.87%43.87% +0.0%
FIIs 19.89%16.92%8.13%16.76%17.47%19.06% +9.1%
DIIs 5.50%5.28%5.91%6.57%6.19%5.54% -10.5%
Public 30.74%33.93%42.08%32.78%32.47%31.53% -2.9%
No. of Shareholders 2,56,2212,65,7882,55,1532,46,2792,46,6352,47,508 +0.4%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Marksans Pharma Limited's revenue in Q1 FY27?
Marksans Pharma Limited reported revenue of ₹841 crore for the quarter ended June 2026 (Q1 FY27), up 35.6% from ₹620 crore in the same quarter last year, and down 1.8% sequentially over the March 2026 quarter.
What was Marksans Pharma Limited's net profit in Q1 FY27?
Net profit rose 174.8% year-on-year to ₹159 crore, from ₹58 crore. Earnings per share (EPS) came in at ₹3.47.
What is MARKSANS's market capitalisation and P/E ratio?
At the current price of ₹311.00, MARKSANS has a market capitalisation of ₹14,093 crore and a trailing P/E of about 27.0.
Who owns Marksans Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 43.87%, foreign institutional investors (FIIs) 19.06%, domestic institutional investors (DIIs) 5.54%, public shareholders 31.53% of Marksans Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI